Search Results

You are looking at 121 - 130 of 205 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal

ductal carcinoma of the breast in 2007. She received neoadjuvant chemotherapy with dose-dense doxorubicin, cyclophosphamide, and paclitaxel, and subsequently underwent a lumpectomy and axillary lymph node dissection showing residual carcinoma. After whole

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

right breast cancer diagnosed 3 years before presentation, which was treated with mastectomy, sentinel lymph node dissection, and adjuvant cyclophosphamide and doxorubicin (4 cycles); the patient subsequently underwent maintenance therapy with oral

Full access

Michelle T. Ashworth and Adil Daud

chest, abdomen, and pelvis identified no other lesions, and results of a complete right inguinal lymph node dissection were negative. The patient was treated with adjuvant radiotherapy (XRT), complicated by a nonhealing ulcer for 1 year and persistent

Full access

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

-oophorectomy and pelvic and periaortic lymph node dissection for stage III uterine carcinosarcoma in March 2016. She completed 6 cycles of carboplatin and paclitaxel therapy and 4,860 cGy of RT to the pelvic and aortic nodes. She later developed subcutaneous

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson

subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of

Full access

Eleni Efstathiou and Christopher J. Logothetis

-chemotherapy retroperitoneal lymph node dissection . Br J Cancer 1999 ; 80 : 249 – 255 . 55. Howell SJ Shalet SM . Spermatogenesis after cancer treatment: damage and recovery . J Natl Cancer Inst Monogr 2005 ; 34 : 12 – 17 . 56. Brydoy M Fossa SD

Full access

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

Full access

Presenters: Meena S. Moran and A. Marilyn Leitch

avoidance of axillary lymph node dissection (ALND) in many patients. This recommendation is largely based on findings from ACOSOG Z0011 and SINODAR-ONE, in which patients with clinical T1/T2N0 disease with up to 2 positive sentinel nodes fared equally well

Full access

Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom

false-positives and unnecessary invasive procedures. 6 – 8 For example, PET/CT has been shown to be less sensitive for the detection of axillary lymph node metastases than axillary lymph node dissection or even physical examination. 9 Finally, advanced